China Probes Into Cost And Pricing Mechanisms Of Multinational Firms
This article was originally published in PharmAsia News
Executive Summary
Chinese authorities are investigating the cost and pricing mechanisms of multinational pharma, including GSK, Merck, Astellas and Boehringer Ingelheim.